Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Apremilast. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN106866493B reveals a novel chiral induction route for Apremilast. This method offers significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN105348172B details a green synthesis route for Apremilast intermediates. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN105330587A details a high-yield route for 3-Acetamidophthalimide. Offers cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Novel aqueous phase transfer catalysis method for high-purity 3-ethoxy-4-methoxybenzaldehyde, offering green synthesis and cost efficiency for API manufacturing.
Patent CN112645854B details a novel purification method for Apremilast intermediates using PEG-modified catalysts and specific solvent systems to achieve over 99.5% purity.
Novel asymmetric hydrogenation route for Apremilast intermediate offering significant cost reduction and supply reliability for pharmaceutical manufacturing partners seeking high-purity intermediates globally.
Patent CN105218428A analysis reveals high purity Apremilast synthesis route. Delivers cost reduction and supply chain reliability for global pharma manufacturing partners seeking scalable API solutions.
Novel Grignard-based route for Apremilast intermediates ensures high purity and reduced waste, offering supply chain stability for pharmaceutical manufacturing partners.
Patent CN112876403A details a high-yield synthesis of Apremilast EP Impurity C. This route offers cost reduction in API manufacturing and ensures supply chain reliability.
Patent CN110467557A reveals a high-yield one-pot synthesis for Apremilast. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN105085373B details a novel purification method for Apremilast, achieving 99.9% purity via single crystallization, offering significant supply chain and cost advantages for pharmaceutical manufacturers.
Novel patent CN117886725A details a Pd-free synthesis route for apremilast intermediates, offering cost reduction in API intermediate manufacturing and enhanced supply chain reliability for global buyers.
Patent CN104447443B reveals a green Mannich route for Apremilast. Achieve high optical purity and significant cost reduction in pharmaceutical intermediates manufacturing with scalable processes.
Patent CN104447445A details a novel route for apremilast intermediate ensuring high purity and scalable manufacturing for global supply chains.